Phase 1 safety, tolerability, pharmacokinetics and pharmacodynamic results of KCL-286, a novel retinoic acid receptor-ß agonist for treatment of spinal cord injury, in male healthy participants. (2023)
Attributed to:
A phase 1 trial of a retinoic acid receptor beta agonist for the treatment of spinal cord injury
funded by
MRC
Abstract
No abstract provided
Bibliographic Information
Digital Object Identifier: http://dx.doi.org/10.1111/bcp.15854
PubMed Identifier: 37452623
Publication URI: http://europepmc.org/abstract/MED/37452623
Type: Journal Article/Review
Volume: 89
Parent Publication: British journal of clinical pharmacology
Issue: 12
ISSN: 0306-5251